[1] 包云秀, 夏丽飞, 李友勇, 等. 茶树新品种“紫娟”[J]. 园艺学报, 2008, 35(6): 934. [2] 梁名志, 夏涛. 特种紫茶降压活性物质初探[J]. 云南农业大学学报, 2003, 18(4): 378-381. [3] 杨兴荣, 包云秀, 黄玫. 云南稀有茶树品“紫娟”的植物学特性和品质特征[J]. 茶叶, 2009, 35(1): 17-18. [4] Wang QP, Peng CX, Gong JS.Effects of enzymatic action on the formation of theabrownin during solid state fermentation of Pu-erh tea[J]. J Sci Food Agric, 8 JUN, 2011, DOI: 10.1002/jsfa.4480. [5] Gong JS, Peng CX, Chen T, et al. Effects of theabrownin from Pu-erh tea on the metabolism of serum lipids in rats: mechanism of action[J]. J Food Sci, 2010, 75(6): 182-189. [6] 龚加顺, 陈文品, 周红杰, 等. 云南普洱茶特征成分的功能与毒理学评价[J]. 茶叶科学, 2007, 27(3): 287-289. [7] 敬明武, 葛宇杰, 刘科亮. 茶色素胶囊对大鼠辅助调节血脂的研究[J]. 中国现代医生, 2007, 45(5): 18-19. [8] 中华人民共和国卫生部. 保健食品检验与评价技术规范[M]. 2003: 2. [9] 李运曼, 雷志冈, 杨贵成. 辛伐他汀与洛伐他汀的降血脂作用比较[J]. 中国药科大学学报, 2002, 33(5): 448-450. [10] Kopelman PG.Obesity as medical problem[J]. Nature, 2000, 404: 635-643. [11] Carek PJ, Dickerso LM.Current concepts in pharmacological management of obesity[J]. Drugs, 1999, 57(6): 883-904. [12] 扬义生, 洪洁. 减肥药物的应用及研究现状[J]. 世界临床药物, 2003, 11: 654. [13] 范建高, 曾民德, 王国良. 脂肪肝的发病机制[J]. 世界华人消化杂志, 1999, 7(1): 75-76. [14] Chen J, Song W, Redinger R.Effects of dietary cholesterol on hepatic production of lipids and lipoproteins in isolated hamster liver[J]. Hepatology, 1996, 24: 424-431. [15] Bachman AL, Dubin MD, Moukarzel AA.Choline deficiency, a cause of hepatic steatosis during parenteral nutrition that can be reverse with intravenous choline supplementation[J]. Hepatology, 1995, 22: 1399-1405. |